View Item 

Show simple item record

Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey

dc.contributor.authorChey, William D.en_US
dc.contributor.authorEswaren, S.en_US
dc.contributor.authorHowden, C. W.en_US
dc.contributor.authorInadomi, John M.en_US
dc.contributor.authorFendrick, A. Marken_US
dc.contributor.authorScheiman, James M.en_US
dc.date.accessioned2010-06-01T21:45:24Z
dc.date.available2010-06-01T21:45:24Z
dc.date.issued2006-03en_US
dc.identifier.citationCHEY, W. D.; ESWAREN, S.; HOWDEN, C. W.; INADOMI, J. M.; FENDRICK, A. M.; SCHEIMAN, J. M. (2006). "Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey." Alimentary Pharmacology & Therapeutics 23(5): 655-668. <http://hdl.handle.net/2027.42/74799>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74799
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16480405&dopt=citationen_US
dc.format.extent176691 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 Blackwell Publishing Ltden_US
dc.titlePrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Gastroenterology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationum† Division of General Internal Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother† Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, ILen_US
dc.identifier.pmid16480405en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74799/1/j.1365-2036.2006.02810.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2006.02810.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceDel Valle J, Chey WD, Scheiman JM. Chapter 66: Acid-peptic disorders. In: Yamada, T, ed. Textbook of Gastroenterology, 4th edn. Philadelphia, PA: JM Lippincott, 2003: 1321 – 76.en_US
dc.identifier.citedreference2 IMS Health. National Prescription Audit Plus TM, 2004 (January 2004-December 2004).en_US
dc.identifier.citedreferenceWolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888 – 99.en_US
dc.identifier.citedreferencePeloso PM, Scheiman JM. The economic implications of COX-2 specific inhibitors. Am J Med 2001; 110: 50S – 4S.en_US
dc.identifier.citedreferenceBombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520 – 8.en_US
dc.identifier.citedreferenceSilverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247 – 55.en_US
dc.identifier.citedreferenceGoldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20: 527 – 38.en_US
dc.identifier.citedreferenceHippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested cast-control analysis. Br Med J 2005; 330: 1366 – 9.en_US
dc.identifier.citedreferenceLÉvesque LE, Brophy JM, Zhang B. The risk of myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481 – 9.en_US
dc.identifier.citedreferenceGraham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2002; 162: 169 – 75.en_US
dc.identifier.citedreferenceChan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038 – 43.en_US
dc.identifier.citedreferenceU.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 157 – 60.en_US
dc.identifier.citedreferenceArmstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527 – 32.en_US
dc.identifier.citedreferenceSingh G, Ramey DR, Morfield D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530 – 6.en_US
dc.identifier.citedreferenceScheiman JM, Fendrick AM. NSAIDs without a prescription: over-counter access, under counted risks. Am J Gastroenterol 2002; 97: 2159 – 60.en_US
dc.identifier.citedreferenceHayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 2002; 136: 161 – 72.en_US
dc.identifier.citedreferenceWeil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827 – 30.en_US
dc.identifier.citedreferenceDerry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 2000; 321: 1183 – 7.en_US
dc.identifier.citedreferenceLai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033 – 88.en_US
dc.identifier.citedreferenceKelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413 – 6.en_US
dc.identifier.citedreferenceLaine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395 – 402.en_US
dc.identifier.citedreferenceLanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Coxibs, NSAIDs, Aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology 2005; 128: A - 94 ( abstract 629 ).en_US
dc.identifier.citedreferenceHuang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14 – 22.en_US
dc.identifier.citedreferenceCampbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97: 2208 – 14.en_US
dc.identifier.citedreferenceHawkey CJ, NÆ;sdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51: 336 – 43.en_US
dc.identifier.citedreferenceChan FKL, To KF, Wu JCY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002; 359: 9 – 13.en_US
dc.identifier.citedreferenceLai KC, Lam SK, Chu CM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trial. Aliment Pharmacol Ther 2003; 18: 829 – 36.en_US
dc.identifier.citedreferenceSaad R, Chey WD. A clinician's guide to the diagnosis and treatment of H. pylori. Clev Clin J Med 2005; 72: 109 – 26.en_US
dc.identifier.citedreferenceFendrick AM, Bandekar RR, Chernew ME, et al. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Care Res 2002; 47: 36 – 43.en_US
dc.identifier.citedreferenceSpiegel BMR, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795 – 806.en_US
dc.identifier.citedreferenceMukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954 – 9.en_US
dc.identifier.citedreferenceLanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004; 20: 321 – 31.en_US
dc.identifier.citedreference33 American Medical Association. Physicians in the United States and Possessions by Selected Characteristics. Chicago: c. 1995–2004 [updated 2004 Jun 24; cited 2004 Nov. 12]. Available at: http://www.ama-assn.org/ama/pub/category/2688.htmlen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2006.02810.x.pdf
Size:
172.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.